Deubiquitinating Enzyme UCH-L1 Regulates Neuronal Ca<sup>2+</sup> Signaling
Ubiquitination influences a myriad of biological processes, such as the trafficking or degradation of ubiquitin-tagged target proteins. This posttranslational modification can be reversed by deubiquitinating enzymes (DUBs) that counterbalance the action of E3 ubiquitin ligases. We investigated the impact of PR-619, a membrane-permeable and broad-spectrum DUB inhibitor, on the entry of Ca<sup>2+</sup> through native voltage-gated Ca<sup>2+</sup> channels (VGCCs) of cultured embryonic cortical neurons. Fura-2-based Ca<sup>2+</sup> imaging experiments showed that PR-619 reduced the cytosolic Ca<sup>2+</sup> rises induced by depolarization by affecting mainly dihydropyridine-sensitive (L-type) VGCCs. This inhibition was sensitive to dynamin inhibitor Myr-Dip and lysosomal agents chloroquine and bafilomycin-A. PR-619 also reduced the amount of Ca<sub>v</sub>1.2 proteins. A pharmacological approach was set out to better delineate the identity of the DUB responsible for this inhibitory action of PR-619. Since UCH-L1 and USP19 are two highly expressed neuronal DUBs, we investigated the effects of selective UCH-L1 (IMP1710, GK13S) and USP19 (ADC141) inhibitors. IMP1710 and GK13S depressed the Ca<sup>2+</sup> uptake through L-type VGCCs, whereas ADC141 and the UCH-L3 inhibitor TCID had no effects. In addition, UCH-L1 inhibition impaired the neuronal Ca<sup>2+</sup> storage capacities of neurons and reduced the Ca<sub>v</sub>1.2 protein levels. Thus, UCH-L1 influences the neuronal uptake and storage of Ca<sup>2+</sup>, which is likely to have important physiological implications. Altogether, these results posit UCH-L1, the main DUB of the brain, as an important regulator of neuronal Ca<sup>2+</sup> homeostasis and add to our understanding of its cellular functions.
Authors
- Alexandre Bouron (ORCID: https://orcid.org/0000-0003-4471-7727)
- Edward W. Tate (ORCID: https://orcid.org/0000-0003-2213-5814)
- Johannes Brand (ORCID: https://orcid.org/0000-0001-7954-9853)
- Pascal Perrier (ORCID: https://orcid.org/0000-0003-2192-4176)
- Marie‐Odile Fauvarque (ORCID: https://orcid.org/0000-0001-5020-3701)
- Gian‐Marvin Kipka (ORCID: https://orcid.org/0000-0001-9128-4499)
- Desirée Loreth (ORCID: https://orcid.org/0000-0003-0827-149X)
- Timothy Harrison (ORCID: https://orcid.org/0000-0001-8782-6697)
- Xavier Jacq
- Laurence Aubry (ORCID: https://orcid.org/0000-0001-7640-1706)
- Malte Gersch (ORCID: https://orcid.org/0000-0003-2767-9589)
- Catherine Meyer‐Schwesinger (ORCID: https://orcid.org/0000-0003-1511-5188)
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Universität Hamburg (DE)
- TU Dortmund University (DE)
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
- The Francis Crick Institute (GB)
- CEA Grenoble (FR)
- University Medical Center Hamburg-Eppendorf (DE)
- Max Planck Institute of Molecular Physiology (DE)
- Almac (United Kingdom) (GB)
- Chemical Genomics Centre (DE)
- Imperial College London (GB)
- Université Grenoble Alpes (FR)
Publication Details
- Journal
- ACS Chemical Neuroscience
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1021/acschemneuro.5c00510
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00